Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
Yanay Ofran, Ph.D., CEO and founder of Biolojic Design: "We are excited about the opportunity to work with Teva and bring hope to patients.
- Yanay Ofran, Ph.D., CEO and founder of Biolojic Design: "We are excited about the opportunity to work with Teva and bring hope to patients.
- The potential therapy we designed for Atopic Dermatitis and Asthma is another example of how AI can revolutionize drug development.
- Under the terms of the agreement, Teva will receive exclusive rights to develop, manufacture and commercialize BD9 worldwide.
- Biolojic is also eligible to receive tiered royalties in the mid-single to low-double digit on product sales should Teva successfully commercialize a therapy.